Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Cytori Therapeutics, Inc. (NASDAQ: CYTX).

Full DD Report for CYTX

You must become a subscriber to view this report.


Recent News from (NASDAQ: CYTX)

Cytori Therapeutics' (CYTX) CEO Marc Hedrick on Q1 2018 Results - Earnings Call Transcript
Cytori Therapeutics Inc (CYTX) Q1 2018 Earnings Conference Call May 10, 2018 5:30 PM ET Executives Marc Hedrick – President and Chief Executive Officer Tiago Girão – Vice President of Finance and Chief Financial Officer Analysts Jason Kolbert – H.C. ...
Source: SeekingAlpha
Date: May, 11 2018 11:46
Cytori Therapeutics misses by $0.03, misses on revenue
Cytori Therapeutics (NASDAQ: CYTX ): Q1 EPS of -$0.07 misses by $0.03 . Revenue of $1.6M (-0.6% Y/Y) misses by $0.83M . Shares +1.2% . Press Release More news on: Cytori Therapeutics Inc, Earnings news and commentary, Stocks on the move, Healthcare stocks news, ,
Source: SeekingAlpha
Date: May, 10 2018 16:40
Cytori Reports Q1 2018 Business and Financial Results
SAN DIEGO, May 10, 2018 (GLOBE NEWSWIRE) -- Cytori Therapeutics (NASDAQ:CYTX) (“Cytori” or the “Company”) today announced Q1 2018 financial results and provided updates on corporate development.  Q1 2018 net loss was $4.4 million, or $0.07 per share. Op...
Source: GlobeNewswire
Date: May, 10 2018 16:25
Cytori to Webcast First Quarter Financial Results on May 10
SAN DIEGO, May 07, 2018 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) will provide a live webcast of its first quarter financial results and business update on Thursday, May 10, 2018 at 5:30 PM Eastern Time. The dial-in information is as follows:     &#x...
Source: GlobeNewswire
Date: May, 07 2018 16:15
Cytori Provides Update on US Manufacturing and EU Approval Plans for ATI-0918, Liposomal Doxorubicin
SAN DIEGO, April 30, 2018 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc.  (Nasdaq:CYTX) (“Cytori” or “the Company”) today provided an update on its plans for US manufacturing and EU approval for its ATI-0918 liposomal doxorubicin product. ATI-0918 has been d...
Source: GlobeNewswire
Date: April, 30 2018 08:30
Enrollment Completed in ADRESU Clinical Trial of Cytori Cell Therapy(TM) for Stress Urinary Incontinence
SAN DIEGO and TOKYO, March 28, 2018 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) announced today that full enrollment has been reached in the ADRESU investigator-initiated clinical trial of Cytori Cell Therapy™ for men with stress urinary incontinence as a complic...
Source: GlobeNewswire
Date: March, 28 2018 12:00
Blog Exposure - Biohaven Reported Positive Top-line Results For its Two Pivotal Phase-3 Trials of Rimegepant
Stock Monitor: Cytori Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 28, 2018 / Active-Investors.com has just released a free research report on Biohaven Pharma Holding Co. Ltd. (NYSE: BHVN ) ("Biohaven"). If you want access to this report all you need to do is ...
Source: ACCESSWIRE IA
Date: March, 28 2018 07:40
Premarket analyst action - healthcare
Endocyte (NASDAQ: ECYT ) initiated with Outperform rating and $20 (150% upside) price target at Wells Fargo. Shares up  4%  premarket on modest volume. More news on: Endocyte, Inc., Corcept Therapeutics Incorporated, Masimo Corporation, Healthcare stocks news, Stocks on the move,...
Source: SeekingAlpha
Date: March, 09 2018 08:12
Cytori Therapeutics' (CYTX) CEO Marc Hedrick on Q4 2017 Results - Earnings Call Transcript
Cytori Therapeutics Inc (CYTX) Q4 2017 Earnings Conference Call March 8, 2018 5:30 PM ET Executives Marc Hedrick - President and Chief Executive Officer John Harris - Vice President & General Manager of Cell Therapy Tiago Girão - Vice President Finance and Chief Financia...
Source: SeekingAlpha
Date: March, 09 2018 02:38
Cytori Therapeutics misses by $0.39, misses on revenue
Cytori Therapeutics (NASDAQ: CYTX ): FY EPS of -$0.65 misses by $0.39 . Revenue of $6.41M (-43.7% Y/Y) misses by $8.51M . Press Release More news on: Cytori Therapeutics Inc, Earnings news and commentary, Healthcare stocks news, ,
Source: SeekingAlpha
Date: March, 08 2018 16:37

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-170.360.3350.360.3153253,523
2018-08-160.320.330.360.315639,043
2018-08-150.340.320.380.32432,115
2018-08-140.380.400.420.37362,924
2018-08-130.450.380.450.37373,454

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1724,97638,42365.0027Short
2018-08-16100,047172,91857.8581Short
2018-08-1526,57561,68543.0818Short
2018-08-1469,700111,49862.5123Short
2018-08-1378,19788,18088.6788Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CYTX.


About Cytori Therapeutics, Inc. (NASDAQ: CYTX)

Logo for Cytori Therapeutics, Inc. (NASDAQ: CYTX)

Not available

 

Contact Information

 

 

Current Management

  • Christopher J. Calhoun / President, CEO
  • Ari E. Bizimis / CFO

Current Share Structure

  • Market Cap: $17,066,536 - 05/15/2018
  • Issue and Outstanding: 59,819,615 - 01/31/2018

 


Recent Filings from (NASDAQ: CYTX)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 11 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 10 2018
General form for registration of securities under the Securities Act of 1933
Filing Type: S-1Filing Source: edgar
Filing Date: April, 27 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: April, 10 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: April, 10 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 06 2018
Pre-effective amendment to an S-3 filing
Filing Type: S-3/AFiling Source: edgar
Filing Date: April, 06 2018
Preliminary proxy statement providing notification matters to be brought to a vote
Filing Type: PRE 14AFiling Source: edgar
Filing Date: March, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 16 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 09 2018

 

 


Daily Technical Chart for (NASDAQ: CYTX)

Daily Technical Chart for (NASDAQ: CYTX)


Stay tuned for daily updates and more on (NASDAQ: CYTX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CYTX)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CYTX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of CYTX and does not buy, sell, or trade any shares of CYTX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/